Silva Pharmaceuticals Limited

সিলভা ফার্মাসিউটিক্যালস্ লিমিটেড

Ref: SPL/SD/2026/82
Date: November 12, 2026

1. The Chairman
Bangladesh Securities and Exchange Commission (BSEC)
Dhaka-1207

2. Managing Director
Dhaka Stock Exchange PLC (DSE), Dhaka-1229

3. Managing Director
Chittagong Stock Exchange PLC (CSE), Chittagong

Subject: Price Sensitive Information (PSI) regarding the adoption of the unaudited financial statements of Silva Pharmaceuticals Limited for the First Quarter (Q1) ended September 30, 2026.

Dear Sir,

We are pleased to inform you that the Board of Directors of Silva Pharmaceuticals Limited, at its 112th Meeting held on Thursday, November 12, 2026, at 2:40 P.M., considered and adopted the unaudited financial statements of the Company for the First Quarter (Q1) ended September 30, 2026. The key financial indicators, along with the comparative figures for the corresponding period of the previous year, are presented below:

Particular	30-Sep-2026	30-June-2026
Net Asset Value Per Share (NAVPS) *	Tk. 14.04	Tk. 14.29
Particular	**01-Jul-2026 to 30-Sep-2026**	**01-Jul-2025 to 30-Sep-2025**
Earnings Per Share (EPS)*	Tk. (0.25)	Tk. (0.26)
Net Operating Cash flow Per Share (NOCFPS)*	Tk. (0.17)	Tk. 0.15

*Reason for the deviation in EPS, NAVPS & NOCFPS:

During the quarter under review, the Company's sales revenue decreased in the corresponding quarter of the previous year, primarily due to significant turnover within the field force sales team, which adversely affected the Company's sales volume.

Despite the decline in sales revenue, the Company's net loss after tax decreased in the corresponding previous period, indicating an improvement in its financial performance. Consequently, Earnings Per Share (EPS) improved slightly to BDT (0.25) from BDT (0.26).

The decrease in Net Asset Value Per Share (NAVPS) was primarily attributable to the accumulated impact of the Company's continued operating losses, which adversely affected its net asset position.

Furthermore, Net Operating Cash Flow Per Share (NOCFPS) deteriorated in the corresponding previous period. This negative movement was primarily attributable to lower collection of trade receivables coupled with increased short-term payments to suppliers during the period.

This is for your kind information and record.

Thanking you

Yours Sincerely,

Md. Iqbal Hossain
Company Secretary

Corporate & Registered Office:
House # 65, Road # 8/A (New)
Dhanmondi, Dhaka-1209, Bangladesh
Phone : +880-2-55000692, 8191336
Fax : +880-2-55000693
Email : info@silvapharma.com
Web : www.silvapharma.com

Factory:
Main Road, Maijdee Court
Noakhali, Bangladesh
Phone: +880-321-63301
Fax: +880-321-63303
Email: factory@silvapharma.com